Your shopping cart is currently empty

ANT3310 is an inhibitor of broad-spectrum covalent Serine β-Lactamase with IC50s ranging from 1 nM to 175 nM for AmpC, CTX-M-15, TEM-1, OXA-48, OXA-23, and KPC-2. ANT3310 can be used in studies about bacterial infection.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $34 | In Stock | In Stock | |
| 5 mg | $80 | In Stock | In Stock | |
| 10 mg | $133 | In Stock | In Stock | |
| 25 mg | $283 | In Stock | In Stock | |
| 50 mg | $455 | In Stock | In Stock | |
| 100 mg | $672 | Inquiry | Inquiry | |
| 1 mL x 10 mM (in DMSO) | $89 | In Stock | In Stock |
| Description | ANT3310 is an inhibitor of broad-spectrum covalent Serine β-Lactamase with IC50s ranging from 1 nM to 175 nM for AmpC, CTX-M-15, TEM-1, OXA-48, OXA-23, and KPC-2. ANT3310 can be used in studies about bacterial infection. |
| In vitro | ANT3310 shows a low in vitro cytotoxicity (IC50 > 100 μM), cardiotoxicity (inhibition of the hERG potassium ion channel) and genotoxicity in HepG2 cell. ANT3310 (0.006 to 3 000 nM) inhibits a series of Serine β-Lactamase including AmpC, CTX-M-15, TEM-1, OXA-48, OXA-23, and KPC-2, with IC<>50 values ranging from 1 nM to 175 nM[1]. |
| In vivo | In male Swiss albino mice, ANT3310 (1 mg/kg; i.v.) shows a T1/2 value of 0.64 h, AUC value of 412 ng•h/mL, and Cl value of 40 mL/min/kg. In the murine thigh infection model, ANT3310 (25, 50 and 100 mg/kg; i.v.) reduces bacterial burdens in a dose-dependent manner to levels below that of the initial starting inoculum at the highest dose, when treated with the combination of MEM[1]. |
| Molecular Weight | 262.19 |
| Formula | C6H8FN2NaO5S |
| Cas No. | 2410688-61-6 |
| Smiles | [Na+].[O-]S(=O)(=O)ON1[C@H]2CN([C@H](F)CC2)C1=O |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (190.7 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (3.81 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.